---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-002831"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:54:31.969274+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipocine licenses TLANDO franchise to Verity Pharma for $11M upfront, up to $259M milestones plus royalties

## Summary
- Exclusive US/Canada rights to TLANDO and TLANDO XR; Lipocine receives $11M license fee ($2.5M paid, $5M due Feb 1, 2024).
- Eligible for up to $259M in development and sales milestones plus tiered royalties of 12–18% on US/Canada net sales.
- Commercialization transitions to Verity Pharma effective Feb 1, 2024; Verity handles all regulatory and marketing obligations.
- Lipocine retains all rights outside US/Canada and all non-TRT indications globally.

## SEC filing metadata
- accession: 0001493152-24-002831
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/0001493152-24-002831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-002831
- JSON: https://secwatch.observer/filing/0001493152-24-002831.json
- Plain text: https://secwatch.observer/filing/0001493152-24-002831.txt

## Key facts
- Material Agreements
  Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).
  - Action: entry
  - Agreement: license
  - Counterparty: Gordon Silver Limited and Verity Pharmaceuticals, Inc.
  - Value: $11 million license fee
  - Effective: 2024-01-12
  source text: On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/0001493152-24-002831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.